Treating to Target with Novel Agents in Rheumatoid Arthritis

Activity Overview

This advanced activity, comprised of complex cases, will challenge you to select appropriate answers, benchmark your scores against your peers, and allow you to benefit from the practical pearls of wisdom from experts in rheumatology.

CE Credit Expired

Target Audience

Rheumatologists – Relevant Terms: Rheumatoid Arthritis

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Utilize appropriate risk-assessment and monitoring tools for patients with rheumatoid arthritis (RA) to assess disease activity and direct individualized management decisions
  • Integrate new and emerging IL-6 directed therapies in RA for individualized treatment plans based on safety and efficacy data, patient selection data, and the rationale for targeting the IL-6 pathway
  • Incorporate strategies for a collaborative approach to RA care that includes a multidisciplinary team of health professionals and includes patient preferences into treatment selection

Activity Faculty

Vibeke Strand, MD, MACR, FACP

Vibeke Strand, MD, MACR, FACP

Adjunct Clinical Professor
Division of Immunology/Rheumatology
Stanford University School of Medicine
Stanford, CA

Martin Jan Bergman, MD, FACR, FACP, FCPP

Martin Jan Bergman, MD, FACR, FACP, FCPP

Clinical Associate Professor, Medicine
Drexel University School of Medicine
Philadelphia, PA

Eric M. Ruderman, MD

Eric M. Ruderman, MD

Professor of Medicine, Department of Rheumatology
Northwestern University
Chicago, IL